Microsoft word - 8-30-005 treatment of malaria - june 2009_ab and jk revised _3_.doc

The following guidelines have been adapted from the 2004 Canadian recommendations for the prevention
and treatment of malaria among international travellers. Canada Communicable Disease Report -
Supplement (Vol 30, June 2004):
rmtc/04vol30/30s1/index.html. The 2006 WHO Guidelines for the Treatment of Malaria are also a useful
Management of malaria depends on several factors. There are three main questions which must be
addressed before initiating treatment.
1. Is this infection caused by Plasmodium falciparum?
This is critical as treatment varies according to the species of malaria. P. falciparum can cause life-threatening disease in non-immune persons, and should be considered a medical emergency. 2. Is this a severe or complicated infection?
Severe P. falciparum malaria is a medical emergency, and the Infectious Disease Service should
be consulted immediately
This can be determined using the criteria listed below. Severe or complicated
malaria, regardless of causative species, requires parenteral therapy and sometimes an exchange
transfusion. While the overwhelming majority of severe infections are caused by P. falciparum, in rare
instances, P. vivax can also cause severe disease, characterized by the clinical manifestations below. In
addition, P. knowlesi, a simian malaria parasite, has emerged from countries of Southeast Asia including
Thailand, Myanmar, Malaysia, the Philippines, and Singapore, and like P. falciparum, can cause a severe
and fatal infection.
Criteria for Severe falciparum Malaria:
Asexual forms of Plasmodium falciparum on blood smear or compatible history
Any one or more of the following features:
ƒ Impaired consciousness or unrousable coma with GCS <10
ƒ Prostration with extreme weakness
ƒ Severe normocytic anemia (hemoglobin <50 g/L)
ƒ Acute renal failure with urine output <400 mL/24 hours and serum creatinine >265 micromol/L
ƒ Pulmonary edema or acute respiratory distress syndrome
ƒ Hypoglycemia (plasma glucose <2.2 mmol/L)
ƒ Shock with systolic blood pressure <80 mmHg
ƒ Spontaneous bleeding/disseminated intravascular coagulation
ƒ Repeated generalized convulsions (>2 within 24 hours)
ƒ Acidemia/acidosis (arterial pH <7.25 or plasma bicarbonates <15 mmol/L or venous lactate >15
ƒ Macroscopic hemoglobinuria not associated with oxidant drugs and RBC enzyme defects ƒ Jaundice detected clinically or total serum bilirubin >50 micromol/L ƒ Parasitemia of >5% in non-immune individuals 3. Is the organism likely to be drug resistant?
Therapy will have to be modified accordingly. In most areas in the world where malaria is transmitted it is caused by drug resistant parasites. When in doubt treat all falciparum malaria as drug resistant. For more information on malaria risk by geographic areas please refer to the Canadian Recommendations for the Prevention and Treatment of Malaria Among International Travellers 2004, Appendix I: MALARIA (cont'd)
Quick Reference to Global Distribution of Drug Resistant Plasmodium spp.

Multi-drug resistant P.
P. falciparum
P. vivax

**Severe P. falciparum malaria is a medical emergency, and the Infectious Disease Service should
be consulted immediately**

A detailed geographic history is essential to the management of malaria. P. falciparum malaria acquired
in areas where drug resistance is known to occur should be treated as chloroquine-resistant infections.
Severe P. falciparum infections may have a mortality rate of 30% or higher. These patients require
immediate hospitalization and urgent intensive medical management. As a general rule, all non-
immune patients with P. falciparum
malaria, whether severe or not, should be considered for
admission to hospital in order to ensure tolerance of antimalarials and to detect complications and
early treatment failure.
All patients with severe infections, regardless of causative species, (including those who are pregnant in
the second and third trimester), and all patients unable to tolerate oral drugs, should receive intravenous
which is the WHO treatment of choice for complicated malaria. Artesunate is an artemisinin
derivative that results in a more rapid parasite clearance, significant reduction in mortality and
hypoglycemia and is better tolerated and easier to administer than quinine injection. Pregnant women in
the first trimester with severe malaria infections should receive intravenous quinine. If IV quinine is not
readily available, the benefit of artesunate in the first trimester outweighs the risk of inadequate treatment
of severe malaria in both mother and fetus. Intravenous artesunate and quinine (quinine dihydrochloride)
are "Special Access" drugs in Canada, but are available at the University Health Network. During
daytime hours, IV artesunate and quinine are available through the inpatient Central Pharmacy (14-3467).
After hours, the on-call pharmacist should be paged to release the drug of choice from a locked depot in
the Emergency Room of Toronto General Hospital.
Falciparum malaria in pregnancy
P. falciparum
infection in pregnancy is associated with increased risk of severe malaria and its associated
complications, particularly pulmonary edema and hypoglycaemia, as well as low birth weight, adverse
fetal outcome, increased maternal anemia. Administration of appropriate antimalarial therapy should not
be delayed. In the case of severe malaria in pregnancy, consultation from Infectious Disease, Tropical
Diseases, and Obstetrics Services should be sought immediately.
MALARIA (cont'd)
CHEMOTHERAPY FOR SEVERE MALARIA (usually caused by P. falciparum)


Artesunate 2.4 mg/kg per dose IV at 0, 12, 24, and 48 hours (total dose 9.6 mg/kg). Each dose should be administered IV push over 1-2 minutes into an established IV line. The drug is reconstituted in phosphate buffer (supplied with the drug) according to the instructions supplied. Artesunate may be mixed with 5 mL of 5% dextrose or normal saline prior to injection if desired. First dose should be administered STAT. Once reconstituted, administer artesunate within one hour of preparation. If available a 0.8 micron hydrophilic polyethersulfone syringe filter (e.g., PharmAssure®, Supor
membrane) should be used to inject the drug. The filter is inserted between the syringe and the
If a suitable syringe filter is not available, do not delay in administering any dose of artesunate.
An in-line filter is preferred but is not mandatory. Note: Dosing is weight based; there is no maximum dose. Dose obese and pediatric patients based on
actual body weight. Patients should be observed for 30 minutes following administration for signs of an
allergic reaction. Dose adjustment of artesunate is not required in renal or liver dysfunction.
plus one of the following follow-on oral agents (to start 4-hours after last dose of IV artesunate)†:
Malarone™ (atovaquone 250mg/proguanil 100mg) with food (preferred agent unless patient
received Malarone prophylaxis, is pregnant, or has CrCl<30ml/min)
Adult Dose:
5-8 kg: 2 pediatric* tablets daily x 3 days 9-10 kg: 3 pediatric tablets daily x 3 days 21-30 kg: 2 adult tablets daily x 3 days 31-40 kg: 3 adult tablets daily x 3 days *1 pediatric tablet contains 62.5 mg atovaquone + 25 mg proguanil
Adult Dose:
2 mg/kg (to a maximum of 100 mg) bid for 7 days Note: Contraindicated if age <8 years or in pregnancy.
Only use if patient is unable to take Malarone or doxycycline or if patient is pregnant.
20 mg/kg/day orally, divided TID or QID for 7 days

†In the rare case of a patient who is unable to tolerate oral medications following 4 doses of
artesunate, artesunate can be continued daily for 7 days total, or the patient can receive a 7-day
course of IV doxycycline (100 mg q12h or 2mg/kg q12h [max 100 mg] for pediatric patients) OR a
7-day course of IV clindamycin (10 mg/kg loading dose, followed by 5 mg/kg IV q8h).

MALARIA (cont'd)

Loading Dose:
Without an infusion pump:
quinine (base) 16.7 mg/kg [quinine dihydrochloride (salt) 20 mg/kg]
diluted in 10 mL/kg isotonic fluid by intravenous infusion over 4 hours
followed immediately by a maintenance dose.
If an infusion pump is available:
quinine(base) 5.8 mg/kg [quinine dihydrochloride (salt) 7 mg/kg] intravenously by infusion
pump over 30 minutes followed immediately by a maintenance dose.
Note: Loading dose should not be used if patient received quinine, quinidine or mefloquine within
the preceding 12 to 24 hours.

Maintenance Dose:

quinine (base) 8.3 mg/kg [quinine dihydrochloride (salt) 10 mg/kg]
diluted in 10 mL/kg of isotonic fluid by intravenous infusion over 4 hours, every
8 hours.
7-days total of quinine therapy is recommended for P. falciparum
infections acquired in Southeast Asia. 3-day quinine therapy is recommended for
all other regions of acquisition (Africa, Latin America, etc.). In patients requiring
more than 48 hours of parenteral therapy, reduce the quinine maintenance dose
by one-third to one-half.
As soon as the patient is able to swallow, step down to a 3-day course of:
Malarone™ (dosing as above). Malarone™ is the preferred oral agent unless the
patient received Malarone™ prophylaxis, is pregnant, or has a CrCl of less than
30 mL/min.
oral quinine tablets (2 tablets tid; 300 mg salt/tablet) PLUS a second agent as
below (doxycycline or clindamycin) to complete 3-7 days of quinine therapy and
7-days of doxycycline or clindamycin.
plus a second agent (to begin concurrently with IV quinine or immediately after):
Adult Dose:
2 mg/kg (to a maximum of 100 mg) q12h/bid for 7 days Note: Contraindicated if age <8 years or in pregnancy.
* The IV formulation of doxyxyxline is no longer available on the Canadian market. It is available
through the Health Canada Special Access Program only.
MALARIA (cont'd)
Clindamycin (to be used in pregnancy)
10 mg/kg (loading dose) intravenously, followed by 5 mg/kg every 8 hours until blood is clear of asexual parasites or oral therapy is tolerated (300 mg base PO q6h [20 mg/kg/day orally divided tid-qid] to complete a 7-day course)
Uncomplicated P. falciparum infections unequivocally acquired in a chloroquine-sensitive zone may be
treated with chloroquine alone. Those infections that were possibly or definitely acquired in drug-
resistant zones should be treated with Malarone™ (atovaquone/proguanil) alone or quinine plus a second
drug. If the patient can tolerate oral quinine, then it and the second drug – either doxycycline or
clindamycin - may be administered simultaneously or sequentially (start quinine first) orally. If the
patient cannot tolerate oral therapy then administer the drugs parenterally.

When quinine is administered to a patient who has taken mefloquine or halofantrine in the previous
2 weeks, there is a risk of drug-induced cardiac arrhythmia; if possible, such patients should be monitored
Chloroquine Phosphate (Aralen®) 150 mg base/tablet
Adult Dose:
Note: This is usually given as 2 tablets bid on days 1 and 2, and 2 tablets once on day 3.
**Chloroquine is safe in all trimesters of pregnancy; dose as above**
Pediatric Dose:

Malarone™ (atovaquone 250mg/proguanil 100mg) with food
Adult Dose:
5-8 kg: 2 pediatric* tablets daily x 3 days 9-10 kg: 3 pediatric tablets daily x 3 days 21-30 kg: 2 adult tablets daily x 3 days 31-40 kg: 3 adult tablets daily x 3 days *1 pediatric tablet contains 62.5 mg atovaquone + 25 mg proguanil

Quinine Sulfate 250 mg base/300 mg salt/tablet
Adult Dose:
2 tablets tid for 3-7 days (7 days if acquired in Southeast Asia) 7.5 mg base/kg (maximum 500 mg base) tid for 7 days plus one of (either concurrently with quinine or immediately after)

Adult Dose:
MALARIA (cont'd)
2 mg/kg (to a maximum of 100 mg) tid for 7 days Note: Contraindicated if age <8 years or in pregnancy.
Only use if patient is unable to take Doxycycline or if patient is pregnant.
Adult Dose:

Or (subject to future availability through the special access programme)

Co-artemether (artemether 20mg/lumefantrine 120mg) with food
The fixed dose combination of artemether (20 mg) and lumefantrine (120 mg) (Co-artemether;
Coartem®) is recommended by several national and international health authorities (including the
WHO) for treatment of uncomplicated malaria. Co-artemether is effective against multi-drug
resistant P. falciparum and results in rapid parasite clearance and symptom resolution. Co-artemether
has been recently licensed by the U.S. FDA for treatment of uncomplicated P. falciparum malaria,
and may become available in Canada via the special access program in the future. The adult dosage
consists of 6 doses over 3 days, and has an excellent safety and tolerability profile. It is
contraindicated during pregnancy, and needs to be taken with food as lumefantrine absorption is
enhanced by co-administration of fat.

Adult Dose:
4 tablets (80 mg / 480 mg) as a single dose, then 4 tablets again after 8 hours, then 4 tablets every 12 hours for 2 days 5-<15 kg: 1 tablet (20 mg / 120 mg) as a single dose, then 1 tablet again after 8
hours, then 1 tablet every 12 hours for 2 days
15-<25 kg: 2 tablets (40 mg / 240 mg) as a single dose, then 2 tablets again after
8 hours, then 2 tablets every 12 hours for 2 days
25-<35 kg: 3 tablets (60 mg / 360 mg) as a single dose, then 3 tablets again after
8 hours, then 3 tablets every 12 hours for 2 days
>35 kg: As per adult dose

(dosing as above to complete 3-7 days)
Clindamycin (as above to complete 7 days)
Many ancillary treatments have been suggested for the treatment of malaria but few have been shown to
improve outcome. The use of steroids to treat severe or cerebral malaria has been associated with worse
and should be avoided. In cases of complicated P. falciparum infection or hyperparasitemia
(>5% parasitemia in non-immune individuals), exchange transfusion has been used on an experimental
basis as a potential life-saving procedure. In all cases of severe malaria, please consult the Infectious
Disease Service immediately by paging the on-call resident. Tropical Diseases consultation can be
arranged by contacting Dr. Kevin Kain at 416-340-3535 or Dr. Jay Keystone at 416-340-3671 or 416-
340-3675 (clinic number) or on his cellphone 416-606-5868 or through locating.
MALARIA (cont'd)
Outside of New Guinea (Papua New Guinea and Irian Jaya), chloroquine remains the treatment of choice
for malaria other than falciparum.
Chloroquine Phosphate (Aralen®) 150 mg base/tablet
Adult Dose:
Note: This is usually given as 2 tablets bid on days 1 and 2, and 2 tablets once on day 3.
**Chloroquine is safe in all trimesters of pregnancy; dose as above**
Pediatric Dose:

At present, chloroquine can no longer be relied upon for chemosuppression or treatment of P. vivax
acquired in New Guinea. Expert advice from Tropical Diseases should be sought for the management of
these cases.
P. vivax and P. ovale have a persistent liver phase that is responsible for relapses and is susceptible only
to treatment with primaquine. None of the currently recommended chemosuppressive regimens will
prevent relapses due to these two species of malaria. Relapses can occur weeks to months following initial
infection, regardless of whether or not symptoms of malaria occurred. In order to reduce the risk of
relapse following the treatment of symptomatic P. vivax or P. ovale infection, primaquine is indicated to
provide “radical cure”. Primaquine should be initiated to overlap with the blood schizonticide agent
(typically chloroquine) in radical cure.
Primaquine is not recommended for routine use to prevent relapsing malaria in the average asymptomatic
returned traveller, however, primaquine is indicated empirically for persons who have had prolonged
exposure in malarious areas (greater than 6 months) where P. vivax or P. ovale constitute a significant
proportion of malaria cases (such Papua New Guinea and other parts of Oceania). This is referred to as
presumptive anti-relapse therapy (PART). Administration of primaquine in a PART regimen should
coincide with the last 2 weeks of chloroquine, mefloquine, or doxycycline prophylaxis or be initiated
during the final week of atovaquone-proguanil prophylaxis.
Primaquine is well tolerated but may cause nausea and abdominal pain which may be diminished by
taking the drug with food. More importantly, primaquine may cause oxidant-induced hemolytic anemia
with methemoglobinemia, particularly in those with a deficiency of G6PD. Patients of Mediterranean,
African, and Asian ethnic origin have a greater risk of hemolysis due to G6PD deficiency. These
individuals, and preferably all potential users of the drug, should have their G6PD level measured before
primaquine therapy is initiated. Primaquine is contraindicated in patients with moderate to severe
deficiency. In mild variants of G6PD deficiency, primaquine has been used safely at a lower dose (0.8 mg
base/kg/week; adult dose of 45 mg base once weekly for 8 weeks) for radical cure of P. vivax or P. ovale
malaria, or as a PART regimen. Patients should be advised to stop their medication and report to a
physician immediately if jaundice or abnormally dark or brown urine is noted.
Primaquine use is contraindicated in pregnancy. P. vivax or P. ovale infections occurring during
pregnancy should be treated with standard doses of chloroquine. Relapses can be prevented by weekly
chemosuppression with chloroquine until after delivery, when primaquine can be safely used in mothers
MALARIA (cont'd)
with normal glucose 6-phosphate dehydrogenase (G6PD) levels. Expert advice from Tropical Diseases
should be sought for cases of malaria in pregnancy.
Primaquine (15 mg base/tablet) (Dosing is for standard radical cure or PART regimen)
Adult Dose:


Drugs Base
Prepared by: Dr. Kevin Kain, Director, Centre for Travel and Tropical Medicine - December 2000 Reviewed and Updated by: Dr. Jay Keystone, Centre for Travel and Tropical Medicine - December 2002; Dr. Andrea Boggild and Dr. Jay Keystone - October 2006 Dr. Andrea K. Boggild and Dr. Jay S. Keystone – June 2009


Microsoft word - icca roadshow report.doc

JUDICIAL DIALOGUE ON THE NEW YORK CONVENTION New Delhi THE CASUARINA HALL at THE INDIA HABITAT CENTRE Mr Shishir Dholakia - Chief Rapporteur Mr Harisankar K S - Co-Rapporteur Introduction This report summarises the proceedings and key conclusions of the ‘Judicial Dialogue on the New York Convention’ that took place in New Delhi on Saturday, 23rd November 2013. The

Keine Angst vor Alterszucker - Ein Ratgeber für normalgewichtige Altersdiabetiker die nicht Insulin spritzen Herr Doktor, habe ich Zucker? Ja, Sie sind an Alterszucker (lateinisch Diabetes mellitus 2) erkrankt. Hat jeder Mensch Zucker im Blut? Ja, unser Körper ist zur Energiegewinnung auf Zucker angewiesen. Der Blutzuckerspiegel wird ganz fein reguliert, er beträgt nüchtern 60

Copyright © 2010 Find Medical Article